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Abstract
The lifespan of people with human immunodeficiency virus (HIV) infection has increased as a result of effective antiretroviral
therapy, and the incidences of the AIDS-defining cancers, non-Hodgkin’s lymphoma and Kaposi sarcoma, have declined.
Even so, HIV-infected individuals are now at greater risk of other cancers, including Hodgkin’s lymphoma (HL). To identify
candidate biomarkers for the early detection of HL, we undertook an accurate mass and elution time tag proteomics
analysis of individual plasma samples from either HIV-infected patients without HL (controls; n=14) and from HIV-infected
patient samples with HL (n=22). This analysis identified 60 proteins that were statistically (p,0.05) altered and at least 1.5-
fold different between the two groups. At least three of these proteins have previously been reported to be altered in the
blood of HL patients that were not known to be HIV positive, suggesting that these markers may be broadly useful for
detecting HL. Ingenuity Pathway Analysis software identified ‘‘inflammatory response’’ and ‘‘cancer’’ as the top two
biological functions associated with these proteins. Overall, this study validated three plasma proteins as candidate
biomarkers for detecting HL, and identified 57 novel candidate biomarkers that remain to be validated. The relationship of
these novel candidate biomarkers with cancer and inflammation suggests that they are truly associated with HL and
therefore may be useful for the early detection of this cancer in susceptible populations.
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Introduction
In the presence of human immunodeficiency virus (HIV)
infection, non-Hodgkin’s lymphoma (NHL) and Kaposi sarcoma
(KS) were the first malignancies used to define acquired immune
deficiency syndrome (AIDS). People with HIV infection are also at
increased risk of a number of other cancers [1]. As people with
HIV infection live longer due to highly active antiretroviral
therapy (HAART), the incidence of these non-AIDS-defining
cancers has increased among HIV-infected individuals. One of the
most common of these malignancies is Hodgkin’s lymphoma (HL),
and it has been estimated that people with HIV/AIDS have a 5.6-
to 14.7-fold increased risk of developing HL compared to the
general population [1–3].
HL is a solid tumor that is comprised of no more than 2% of the
cancerous B lymphocytes. Instead, these lymphocytes secrete a
wide range of cytokines that attract numerous normal leukocytes
that then comprise the large majority of the tumor [4]. Thus, HL
is largely seen as an uncontrolled inflammatory disease [4]. In
people with immunosuppression, HL is believed to result from the
Epstein-Barr virus (EBV). EBV is present in nearly all adults, but
typically only causes HL when the immune system is suppressed,
such as with HIV infection [4].
The increase in non-AIDS-defining cancers has created a
greater need for the early detection of these malignancies
in this susceptible population. It seems likely that HIV-
infected individuals would benefit from a routine, non-invasive
screen for HL, but no such screen exists. Rather, HL patients
are identified after they become symptomatic [5]. Chemo-
therapy and radiation therapy have been shown to be very
effective at causing HL remission, but morbidity and
mortality associated with these treatments is substantial [6].
Early-stage HL is generally treated less intensively, suggesting
that early detection of HL would result in less treatment-
related toxicity. Cancer treatment strategies for HIV-infected
individuals with HL are the same as for non-AIDS subjects
[6], but HIV-infected patients require additional vigorous
supportive care (HAART, antifungals, neutrophil-simulating
growth factors).
To identify candidate biomarkers for HL detection, we
analyzed plasma samples from HIV-infected patients, with or
without HL, using accurate mass tag and time (AMT) tag
proteomics, and thereby identified a set of 60 proteins. As a
group, these proteins are associated with both cancer and
inflammation and therefore are promising candidate biomarkers
for early detection of HL.
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Ethics Statement
The study protocol was approved by the George Washington
University Medical Center Institutional Review Board. Written
informed consent was obtained from all study participants.
Additional approval from the PNNL Institutional Review Board,
which included a review of the George Washington University
Medical Center IRB approval, was obtained before samples were
transferred to PNNL.
Human Subjects and Sample Processing
Frozen, human plasma samples were provided by the AIDS and
Cancer Specimen Resource (San Francisco, CA). The control
subjects (HIV-infected without HL) were chosen to approximately
match the cases (HIV-infected with HL) based on gender and age
(Table 1). In most cases, plasma samples were collected from HIV-
infected subjects with HL that had not received HL chemotherapy
within at least 30 days (n=12). Information on chemotherapy was
unknown for some cases (n=9) and one sample was known to have
been collected within 30 days of chemotherapy. For all processing
and analytical steps, samples were blocked based on HL status and
randomized [7]. The 12 most abundant plasma proteins were
depleted using the Proteome Purify
TM 12 immunodepletion resin
(R&D Systems), according to the manufacturer’s protocol. The
remaining plasma proteins were precipitated using ice-cold
trichloroacetic acid at a final concentration of 10%, followed by
overnight incubation at 4uC and centrifugation at 14,000 x g for 5
minutes. The pellet was washed with cold acetone and dried at
room temperature for 5 minutes prior to suspension in 25 mL of 100
mM ammonium bicarbonate, 8 M urea, 2 M thiourea and 5 mM
dithiothreitol, and heating to 60uC for 30 min. The samples were
then diluted 4-fold with 100 mM ammonium bicarbonate and
CaCl2 was added to 1 mM. Methylated, sequencing-grade trypsin
(Promega, Madison, WI) was added at a substrate-to-enzyme ratio
of 50:1 (mass:mass) and incubated at 37uC for 15 h. Peptides were
then purified by binding to a 1 mL SPE C18 column (Supelco,
Bellefonte, PA) and eluting with 1 mL of methanol. After
concentration in a SpeedVac, the samples were dissolved in 25
mM ammonium bicarbonate and frozen at 220uC until analysis.
Liquid Chromatography-Mass Spectrometry
Peptide samples were analyzed using a custom-built, automated,
high-pressure nanocapillary liquid chromatography (HPLC) system
[8] coupled on-line to a LTQ-Orbitrap mass spectrometer (Thermo
Fisher Scientific). The reversed-phase capillary column was
prepared by slurry packing 3-mm Jupiter C18 bonded particles
(Phenomenex, Torrence, CA) into a 65-cm-long, 75-mm-inner
diameter fused silica capillary (Polymicron Technologies, Phoenix,
AZ). The mobile phase consisted of 0.2% acetic acid and 0.05%
trifluoroacetate in water (A) and 0.1% trifluoroacetate in 90%
acetonitrile, 10% water (B). After loading 5 mL (2.5 mg total) of
peptides onto the column, the mobile phase was held at 100% A for
50 min. Exponential gradient elution was performed by increasing
the mobile phase composition from 0 to 55% B over 115 min. The
HPLC column was coupled to the mass spectrometer by an in-
house manufactured electrospray ionization interface [9]. The
heated capillary inlet temperature and electrospray voltage were
200uC and 2.2 kV, respectively. Data were acquired for 100 min,
beginning 65 min after sample injection (15 min into start of buffer
B gradient). Orbitrap spectra (AGC 5610
5) were collected from
400–2000 m/z at a resolution of 100,000.
The mass spectra were analyzed using the AMT tag approach
[9]. The peak lists for each analysis were matched against a mass
tag database containing 30,573 tryptic peptides that were
previously identified from LC-MS/MS analyses of human plasma
[10–12]. An estimate of the false-positive rate for peptide
identifications in our analysis, which was #6%, was obtained by
searching the sequence-reversed database [13].
Statistics
There were 76 mass spectrometry runs included in the
proteomics data, including at least two analyses for each of the
36 samples. A total of 6460 unique peptides were initially
identified. The data-analysis process first removed peptides for
which there were insufficient identifications to perform a statistical
analysis [14], which reduced the peptide number to 3814. Next,
the peptide abundance measurements were normalized via
regression based on all the peptide signals for that mass
spectrometer run and then averaged across replicate runs for
each sample. The averaged signal intensities were normalized for
each sample based on the median absolute deviation of the signal
intensity for all peptides identified in each sample. Finally, the data
were subjected to two statistical tests to determine peptides having
differential abundance due to either signal intensities or presence-
absence. A non-parametric Mann-Whitney test was performed
using MatLab 2009 to compare signal intensities. Differences in
detection incidence was determined using a modified Chi-square
test, called a G-test [14]. Using either test, 647 peptides were
identified with a p-value of 0.05 or less.
Normalized peptide abundance values were used for protein
inference; the peptide abundance measurements were weighted
and combined to calculate the relative protein abundances in the
two groups using RRollup within DAnTE (http://ncrr.pnl.gov/
software/; reference [15]. Only proteins represented by two or
more unique peptides were analyzed. Peptide redundancy was
reduced with Protein Prophet [16] and by manually selecting
characterized proteins over predicted or hypothetical proteins.
Ingenuity Pathway Analysis
Differentially regulated proteins were analyzed for common
biological functions using Ingenuity Pathway Analysis (IPA;
Ingenuity Systems, Mountain View, CA) software. To infer
significant biological functions, all proteins that were significantly
different between groups and their corresponding ratiometric
Table 1. Subject characteristics.
HIV+ HIV+/HL+
Number 14 22
Gender (M/F) 10/4 20/2
Age (min-max) 53.965.9
a (42–63) 49.268.8 (34–66)
CD4 count
b 4046380 2036224
CD4 count ,200
c 4 (29%) 12 (55%)
HAART
d (yes, no,
unknown)
12, 1, 1 11, 4, 7
Lymph node
involvement
NA
e 6
aMean 6 standard deviation.
bUnits are CD4-positive cell counts per mL blood.
cCD4 counts of less than 200/mL has been used to define the presence of AIDS
in HIV positive subjects.
dIndicates current usage of HAART antiretroviral therapy at the time of the
blood draw. ‘‘Unknown’’ indicates that HAART usage at the time of the blood
draw is unknown. Prior usage is unknown for all subjects.
eNA, not applicable.
doi:10.1371/journal.pone.0029263.t001
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IPA. The significance values for biological function were
determined using the right-tailed Fisher’s Exact Test.
Results and Discussion
To identify potential circulating biomarkers for HL in a
susceptible population, we used the AMT tag LC-MS approach
to compare the plasma proteomes from 36 HIV-infected patients
with or without HL. The HIV-infected patients without HL served
as the control group to identify protein changes associated with
HL. The relatively high-throughput characteristics of this
approach enabled duplicate analyses of each of the 36 plasma
samples, thereby improving data quality. The subject character-
istics are described in Table 1. The proteomics analysis identified
3814 peptides across all of the samples, which corresponded to 629
proteins. Of these 3814 peptides, 647 were significantly different
between the two disease states, which corresponded to 152
proteins (Tables S1 and S2). Sixty of these proteins met our criteria
of being both significantly different between the two groups and
having at least 1.5-fold difference in the normalized signal (Table
S3). This protein list included well-known acute-phase inflamma-
tory proteins, including C-reactive protein and serum amyloid
proteins. To better identify common biological functions within
these 60 proteins, Ingenuity Pathway Analysis (IPA) was utilized.
In general, proteins that were associated with immune responses
and cancer were highly represented in the list of significantly
altered biological functions. Many of the proteins we identified are
known to be secreted by white blood cells, such as those that
infiltrate HL tumors, or by the liver, an important component of
the reticuloendothelial system (Table S3). Similarly, the use of IPA
to identify common biological functions across the 60 proteins
identified ‘‘inflammatory response’’ and ‘‘cancer’’ (Table 2),
suggesting that these proteins have a biological relationship with
HL. Since only 1% to 2% of the mass of an HL tumor is composed
of the cancerous lymphocytes, it may be that the proteins we
identified did not originate from these relatively rare cells. Rather,
these proteins may be the product of a systemic inflammatory
response associated with HL or due to noncancerous leukocytes
that form ,99% of the tumor mass.
At least three of the proteins we identified have been previously
reported to be increased in HL subjects compared to healthy
controls, including C-reactive protein [17], beta-2-microglobulin
[18,19] and lactate dehydrogenase [18]. These prior studies
examined HL in the general population, and did not focus on
HIV-positive subjects. In addition, these studies measured these
proteins by immunoassay, providing analytical verification as well.
In the current study, the presence of HIV in the study population
could be a confounding factor. For example, the HL subjects
appeared to have slightly more advanced cases of HIV, on the
average, as suggested by a trend (p=0.07, t-test) towards lower
CD4-postive cell counts (Table 1), a result which is consistent with
slightly more advanced immunosuppression. Even so, since three
of the proteins we identified are increased in HL subjects without
HIV, it seems clear that the results for these proteins, at least, are
not confounded by differential states of HIV infection. Overall, the
present study independently validates three plasma biomarkers for
HL and identifies an additional 57 novel plasma proteins that
appear to be promising candidate biomarkers based on their
relationships with cancer and inflammation. These candidate
biomarkers remain to be validated in regards to their association
with HL.
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